Skip to main content

Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates.

Publication ,  Journal Article
Schmitz, R; Fitch, ZW; Manook, M; Schroder, PM; Choi, AY; Olaso, D; Yoon, J; Bae, Y; Shaw, BI; Song, M; Kuchibhatla, M; Farris, AB; Kirk, A ...
Published in: Kidney360
December 29, 2022

Preexisting donor-specific antibodies (DSA) to MHC antigens increase the risk of antibody-mediated rejection (AMR) in sensitized transplant recipients and reduces graft survival. Pretransplant desensitization with costimulation blockade and proteasome inhibition has facilitated transplantation in our preclinical nonhuman primate (NHP) model. However, long-term graft survival is limited by rebound of DSA after transplantation. In this study, we performed kidney transplants between highly sensitized, maximally MHC-mismatched NHPs (n=14). At kidney transplantation, primates received T cell depletion with rhesus-specific anti-thymocyte globulin (rhATG; n=10) or monoclonal anti-CD4 and anti-CD8 antibodies (n=4). Maintenance immunosuppression consisted of belatacept and tacrolimus (n=5) or belatacept and rapamycin (n=9) with steroids. Rebound of DSA post-kidney transplantation was significantly reduced compared with maintenance immunosuppression with tacrolimus, mycophenolate, and steroids. Protocol lymph node biopsy specimens showed a decrease in germinal center activity, with low frequencies of T follicular helper cells and class-switched B cells after kidney transplantation. Combined belatacept and rapamycin was superior in controlling viral reactivation, enabling weaning of ganciclovir prophylaxis. Tacrolimus was associated with increased morbidity that included cytomegalovirus and parvovirus viremia and post-transplant lymphoproliferative disorder. All primates in the tacrolimus/belatacept group failed discontinuation of antiviral therapy. Overall, belatacept-based immunosuppression increased AMR-free graft survival by controlling post-transplant humoral responses in highly sensitized NHP recipients and should be further investigated in a human clinical trial.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Kidney360

DOI

EISSN

2641-7650

Publication Date

December 29, 2022

Volume

3

Issue

12

Start / End Page

2116 / 2130

Location

United States

Related Subject Headings

  • Tacrolimus
  • Sirolimus
  • Immunosuppression Therapy
  • Immunity, Humoral
  • Antibodies
  • Animals
  • Abatacept
  • 4202 Epidemiology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schmitz, R., Fitch, Z. W., Manook, M., Schroder, P. M., Choi, A. Y., Olaso, D., … Knechtle, S. J. (2022). Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates. Kidney360, 3(12), 2116–2130. https://doi.org/10.34067/KID.0001732022
Schmitz, Robin, Zachary W. Fitch, Miriam Manook, Paul M. Schroder, Ashley Y. Choi, Danae Olaso, Janghoon Yoon, et al. “Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates.Kidney360 3, no. 12 (December 29, 2022): 2116–30. https://doi.org/10.34067/KID.0001732022.
Schmitz R, Fitch ZW, Manook M, Schroder PM, Choi AY, Olaso D, et al. Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates. Kidney360. 2022 Dec 29;3(12):2116–30.
Schmitz, Robin, et al. “Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates.Kidney360, vol. 3, no. 12, Dec. 2022, pp. 2116–30. Pubmed, doi:10.34067/KID.0001732022.
Schmitz R, Fitch ZW, Manook M, Schroder PM, Choi AY, Olaso D, Yoon J, Bae Y, Shaw BI, Song M, Kuchibhatla M, Farris AB, Kirk A, Kwun J, Knechtle SJ. Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates. Kidney360. 2022 Dec 29;3(12):2116–2130.

Published In

Kidney360

DOI

EISSN

2641-7650

Publication Date

December 29, 2022

Volume

3

Issue

12

Start / End Page

2116 / 2130

Location

United States

Related Subject Headings

  • Tacrolimus
  • Sirolimus
  • Immunosuppression Therapy
  • Immunity, Humoral
  • Antibodies
  • Animals
  • Abatacept
  • 4202 Epidemiology
  • 3202 Clinical sciences